Lila Bio
Lila Bio develops therapeutic proteins using AI-powered protein design and experimental discovery platforms. Its targeted radiotherapy platform focuses on solid tumors, while its long-acting injectable platform targets non-oncology diseases; the company aims to develop medicines that improve care for people with cancer and other debilitating diseases.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology Research
- Founded
- 2023
- Employees
- 10
- Members see funding amounts. .
- Founders
- Jake Kraft, PhD, Anindya Roy, PhD, Hua Bai, PhD, Sheila Gujrathi, MD
Is this your organization? Claim it
Lila Bio wins $3.65M NIH SBIR grant to develop AI-designed long‑acting injectable for pulmonary hypertension
Lila Bio, spun out of David Baker’s UW lab, won a $3.65 million NIH SBIR grant to develop an AI-designed, long-acting injectable protein therapy aimed at modifying disease in pulmonary hypertension. The funding covers two phases—$605,981 for initial animal studies and $3,049,462 for further animal work and patient lung-tissue studies—and builds on Lila’s 2023 $10M seed raise and prior collaboration with Eli Lilly.
Lila Bio wins $3.65M NIH SBIR grant to build AI-designed proteins for pulmonary hypertension
Lila Bio won a $3.65 million NIH SBIR fast-track grant to develop AI-designed therapeutic proteins for pulmonary hypertension, receiving an initial $605,981 phase followed by $3,049,462 in a second phase. The Seattle startup, founded in 2023 by Jake Kraft and Anindya Roy, previously raised a $10 million seed round and will use the non-dilutive funding to advance candidates toward clinical utility.
Lila Bio wins $3.65M NIH SBIR grant to develop AI-designed protein therapy for pulmonary hypertension
Lila Bio received a $3.65 million NIH SBIR grant to develop AI-designed, long-acting injectable protein therapies that aim to modify the underlying disease in pulmonary hypertension; initial work is in lab and animal testing with further studies planned using patient lung tissue.
People
See all 4-
Anindya Roy Executive Officer, Director, CSO & Co-Founder
-
Jake Kraft CEO & Co-Founder
-
Hua Bai Director of Protein Design & Co-Founder
Online
Questions about Lila Bio
What is Lila Bio?
Lila Bio is a startup based in Seattle that develops therapeutic proteins using AI-powered protein design and experimental discovery platforms.
What is Lila Bio known for?
Lila Bio develops targeted radiotherapy for solid tumors and long-acting injectables for non-oncology diseases, including an AI-designed protein therapy for pulmonary hypertension.
What has Lila Bio been in the news for?
GeekWire reported in November 2026 that Lila Bio won an NIH SBIR grant to develop an AI-designed protein therapy for pulmonary hypertension. Best Technologies reported in November 2026 that the grant supports an AI-designed long-acting injectable for pulmonary hypertension.
Who are the people behind Lila Bio?
Jake Kraft is CEO and co-founder of Lila Bio; Anindya Roy is executive officer, director, CSO and co-founder; and Hua Bai is director of protein design and co-founder. Kimberly Ma is executive and chief development officer.
Who invested in Lila Bio, and how much has it raised?
Members of Seattle Flow see Lila Bio's funding rounds, amounts and investors on its Funding tab. Joining is free.
Where is Lila Bio based?
Lila Bio is based in Seattle.